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Objective: To evaluate the incidence of hemolytic uremic syndrome (HUS) in Belgium and to determine the role of 
verocytotoxin-producing Escherichia coli 0 1  57:H7 and other serotypes (non-0157 VTEC). 
Methods: Twenty-two centers, including the seven university hospitals, registered prospectively all cases of HUS; they 
collected clinical samples for isolation o f  VTEC strains and serum for detection of specific 0-lipopolysaccharide 
anti bodies. 
Results: Forty-seven cases of HUS (including five incomplete cases) were recorded. Three cases were seen in non- 
residents. The incidence of complete HUS in  Belgian residents was 4.3 cases/100 000 in  children c5 years old, 1.8 
cases/100000 when all children < I 5  years were considered, and 0.42/100000 when patients of all ages were taken into 
account. By combining bacteriologic and serologic results, evidence of VTEC infection was obtained in 64% of the 
patients, mainly but not exclusively in  children with prodromal diarrhea. The 13 VTEC isolates belonged to serotypes 
0157:H7 (nine isolates), 026:Hll ,  0121:H-, 0145:H- and 0172:H- (one each) and all produced VT2 (+VT2vh-a in  three 
0157 strains) and were positive for the eaeA gene. 
Conclusions: The incidence rate found in  this study and the high mortality and morbidity linked with this syndrome 
warrant further registration of pediatric and post-diarrheic adult HUS cases and also examination of stools for both 0157 
and non-0157 VTEC strains. For effective prevention of this disease, further study of the serotypes and accessory 
virulence factors associated with HUS is needed. 
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INTRODUCTION 
The hemolytic uremic syndrome (HUS) is the main 
cause of acute renal failure in childhood [l]. It not only 
causes acute morbidity and mortality but can also be 
responsible for long-term sequelae. In a recent report 
with a follow-up of 10 years, in addition to 6% of 
children who died in the acute phase and 4% who went 
into end-stage renal failure, as many as 9% of survivors 
presented severe sequelae and 26% mild defects [3]. 
Cases are generally divided into typical (preceded by 
diarrhea) and atypical (without diarrhea). The latter 
presentation is rare in children and it is generally 
considered to have a poor prognosis [l]. Thrombotic 
thrombocytopenic purpura (TTP), considered to be 
the opposite end of the same spectrum, is characterized 
by the additional presence of fever and fluctuating 
central nervous system abnormalities [l]. Karmali et a1 
have shown that post-diarrheic HUS cases are 
associated with strains of Esclzeviclziu coli that produce 
cytotoxins called verocytotoxins (VTs) or Shiga toxins 
[3,1]. These toxins are also produced by Shigella 
dyseriteviuc type 1,  and this species is responsible for most 
cases of HUS in developing countries [5]. More than 
100 serotypes of E. coli can produce VTs [6]. The most 
frequently isolated VT-producing E.  coli (VTEC) 
serotype, 0357:H7, and strains which manifest the 
same clinical, epidemiologic and pathogenetic features, 
e.g. serotypes 0 3 6 : H l l  and 0 1 1  1:H-, are also known 
as enterohemorrhagic E. coli (EHEC). 
The epidemiology of HUS has mainly been 
studied in North America and the UK, where its 
incidence seems to be increasing. In these countries, 
mainly the 0157:H7 VTEC serotype is involved in 
HUS [7]. In coiitiiiental Europe, the incidence of HUS 
is lower and contrasting data have been published 
concerning the respective roles of 0 1  57:H7 and other 
VTEC serotypes IS]. The objective of the present study 
was to evaluate the incidence of HUS in Belgium and 
to determine the role of 0 1 5 7  VTEC serotypes 
(including 0 1  57:H7 and its non-motile variant 
0157:H-) and of other serotypes (now0157 VTEC). 
MATERIALS AND METHODS 
Participating centers 
The members of the Belgian Society for Infectious 
Diseases and Clinical Microbiology as well as the 
pediatric nephrology centers of the Belgian university 
hospitals were asked to join a multicenter study group 
and to register prospectively all cases of HUS diag- 
nosed in their center during the period from 1 January 
to 31 December 1996. Twenty-two centers, formally 
registered as participants, including the seven Belgian 
university hospitals, were contacted several times to 
make sure that all cases were effectively reported. 
Case definition 
HUS was defined as an acute illness in a previously 
healthy patient characterized by hemolytic anemia with 
evidence of erythrocyte fragmentation on peripheral 
blood smear, thronibocytopenia defined by a platelet 
count of less than 160 00O/pL, and renal failure defined 
by a serum creatinine level higher than 1.0 mg/dL for 
children less than 15 years old and higher than 
3.0 nig/dL for adults. Cases not fulfilling all these 
criteria could be recorded as incomplete cases. 
Case reports 
For each case, the participants were asked to complete 
a questionnaire including demographic, clinical and 
laboratory data. A second questionnaire was sent for 
assessment of short-term follow-up after 3 months or 
more if needed. 
Collection of samples for the diagnosis of VTEC infection 
Participants were asked to send clinical samples to the 
VTEC reference laboratory for isolation of VTEC 
strains, and serum for detecting specific 0-lipopoly- 
saccharide antibodies. For VTEC isolation, a fecal speci- 
men, a rectal swab or a primary enteric agar plate had 
to be sent as early as possible after diagnosis to the 
reference laboratory. Serum samples had to be collected 
in the acute phase and, when possible, a few weeks later. 
Isolation of VTEC from feces and characterization of 
F. coli isolates 
VTEC strains were searched for with a P C R  technique 
previously described 191. Briefly, a suspension of a 
colony sweep taken from the primary MacConkey agar 
plate (or other enteric agar) was used both without 
further treatment and after immunomagnetic separ- 
ation (Dynabeads anti-E. roli 0157,  Dynal, Oslo, 
Norway) in a P C R  reaction using a consensus primer 
pair amplifying VT1, VT2 and its variants [lo]. A 
sample was considered positive only if a t  least two 
repeats of the P C R  reaction starting from the same 
plate were positive. For each PCR-positive plate, 
10-100 colonies were tested separately in order to 
isolate the VTEC strain in pure culture for further 
characterization. After biochemical identification, the 
isolates were agglutinated with 0157  antiserum and 
tested on the H7 antiserum-sorbitol fermentation 
medium [l 11. Further serotyping of non-agglutinating 
strains and phage typing of 0 1 5 7  strains were 
performed by Dr B. Rowe, PHLS, London, except 
for one strain serotyped by Dr  F. Scheutz, Statens 
Seruminstitut, Copenhagen, Denmark. Production of 
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VT was confirmed by cytotoxicity testing on Vero cells 
[13]; the genotype of the B subunit was determined 
with specific P C R  primers [13,14]. Accessory 
virulence factors were detected as previously described 
[Y] by using phenotypic tests for E. coli hemolysins [15] 
and PCR for the eaeA gene [16] and for sequences of 
the 60-MDa virulence plasmid [ 171. 
Detection of specific lipopolysaccharide antibodies 
An indirect hemagglutination assay was used to detect 
antibodies against the lipopolysaccharidic antigens 
(LPS) of 11 E. coli 0 serogroups-0157, 0 2 ,  0 2 6 ,  
091 ,  0103,  0111,  0113,  0128 ,  0131,  0 1 4 5  and 
0172-and of Shigella dyserzteviae type 1. These E. coli 
serotypes were selected because they were identified 
frequently in other HUS studies [7,18], in HUS cases 
in Belgium 1121 (this study) or in other human VTEC 
infections in Belgium [Y]. The LPS was prepared as 
described by Siddons and Chapman [19], using strains 
isolated in our laboratory "3,121 (this study). The 
resulting antigen preparation was stored at -20°C and 
used to sensitize lyophilized red blood cells as described 
by Bitzan and Karch [20]. Unsensitized red blood cells 
were used as control with each investigated patient's 
serum. The indirect hemagglutination was performed 
as described by Bitzan and Karch, but we started with 
a serum dilution of 1:8 or more if the available volume 
of serum was limited. O n  the basis of the data of these 
authors and preliminary unpublished observations from 
our laboratory showing that control patients had only 
exceptionally reverse titers of 256 or higher, we 
considered a reaction as positive ifa titer of 256 or more 
was observed. 
Table 1 Demographic characteristics of the HUS cases 
During the 1-year study period, 47 cases of HUS were 
recorded in 14 of the 32 participating centers. Five 
pediatric cases were incomplete because they did not 
fulfill one of the case definition criteria, i.e. the elevated 
creatininemia. Three patients were non-residents 
transferred to Belgium for therapy. Of the 44 resident 
cases, two were traveling in the Canary Islands when 
they fell ill. Thirty-nine cases of complete HUS were 
recorded in patients residing in Belgium. The 
incidence of complete HUS in Belgian residents 
computed on the basis of population data from the 
National Institute of Statistics was 4.3 cases/100 000 
in children <5 years old, 1.8 cases/100000 when 
all children <15 years old were considered, and 
0.42/100000 when patients of all ages were taken into 
account. To our knowledge, all these cases except two 
siblings were unrelated. They were distributed among 
all Belgian provinces. No clustering in time was 
observed. Demographic characteristics of all recorded 
cases are presented in Table 1. In 38 of the 47 patients 
(34 of the 38 children, and four of the nine adults), a 
prodromal episode of diarrhea was reported. Diarrhea 
was bloody in 20 children but in none of the adult 
cases. In two children without diarrhea, a prodronial 
phase of nausea and vomiting was reported. One  4- 
year-old mentally handicapped boy died during 
transportation to the hospital, and the diagnosis was 
suspected because his sister developed incomplete HUS 
5 days later and had 0157:H7 VTEC isolated from her 
stools. Necropsy findings in the boy-signs of gastro- 
enteritis with reactional mesenteric lymph nodes and 
No. of patients with 
prodromal diarrhea prodromal diarrhea All patients 
No. of patients without 
Sex 
Female 182 ( 1 ) C  4 722 (1) 
< 1  5b (1) 1 hb (1) 
Male 20 (4) 5h 25b (4) 
Age (years) 
1-4 23h (4) 3 26b (4) 
5-14 6 0 6 
15-14 0 0 0 
25-34 1 1 2 
35-44 2 1 3 
45-54 0 1 1 
55-64 0 l b  l h  
>65 1 1 2 
Total 38 (5) 9 47 (5) 
~ ~ 
Includes two non-resident cases 
Includes one non-resident case. 
The numbers in parentheses represent the number of incomplete HUS cases 
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presence of microthrombi in the kidneys and lungs- 
were compatible with the diagnosis. The biochemical 
data on 44 of the 46 other patients (complete data not 
being available in two cases) were characteristic of 
HUS: all had a hemoglobin level of less than 10 nig/dL 
(median of the lowest values 6.8 mg/dL, range: 
3.4-9.6 nig/dL); schizocytes were present in all but 
four, where they were not looked for; all had 
thrombocyte counts lower than 160 000/pL (median of 
the lowest platelet counts 32 250/pL, range <1000- 
118OOO/pL); and all but the five children with 
incomplete HUS had elevated creatininemia (median 
of the highest value in children 3.7 mg/dL, range 
0.6-12.0 nig/dL; median of the highest value in adults: 
6.1 mg/dL, range 3.5-10.9 mg/dL). 
Follow-up data after 3 months were available in 41 
patients. The following complications were recorded. 
Five patients (four children and one adult) had severe 
colitis, three (one child and two adults) pancreatitis, 
two (one child and one adult) septic shock and two 
(both adults) pulmonary hemorrhage. In addition to 
the child who died during transfer to the hospital, three 
adults died, one in septic shock and two from 
pulmonary hemorrhage. The hospital stay in surviving 
patients ranged from 7 to 56 days in children (median 
16 days) and from 11 to 179 days in adults (mednn 30 
days). Among the 34 surviving patients with available 
follow-up data at 3 months, seven (six children and one 
adult) still showed hypertension, five (four children and 
one adult) renal insufficiency, seven (all children) 
proteinuria and one (child) hematuria. 
Stool samples were available in 33 cases. Fourteen 
(42%) yielded a positive PCR,  in one case only after 
inimunoniagnetic separation. The serotypes and 
virulence factors of the 13 VTEC strains that could be 
isolated, nine 0157:H7 and four other serotypes, are 
presented in Table 2. In the last PCR-positive sample, 
no VTEC could be detected among 100 separately 
tested colonies. In addition, urine and blood E. coli 
isolates from one adult patient from whom no stools 
were available were P C R  negative. In 13 of the 34 
patients from whom serum samples were available 
(more than one saniple in only six patients), the 
hemagglutination reaction was positive for at  least one 
of the 0 antigens, with a reverse titer higher than or 
equal to 256. Eleven patients were positive for 0157  
(median reverse titer 2096, range 256-16 384), one for 
0 1 1 1  (titer: 8192) and one for both 0 1 6  and 0157  
(titers of 1024 against both antigens). In addition, the 
results were not interpretable in two patients presenting 
non-specific agglutination of unsensitized red blood 
cells. 
When the results of the P C R  and VTEC isolation 
from stools were combined with serology, 23 of 36 
patients from whom either stools, serum or both were 
available had evidence of VTEC infection, including 
the two children without diarrhea but with vomiting 
and anorexia. When only children or patients with 
diarrhea were taken into account, 22 of 30 and 21 of 
29, respectively, showed evidence of VTEC infection. 
Only one adult patient, a 69-year-old woman with 
prodromal diarrhea, had a positive VTEC result (anti- 
0 1  57 LPS titer of 4096). 
DISCUSSION 
Data on the incidence of HUS are only available from 
countries ofEurope and North America as well as from 
Argentina. Table 3 shows a comparison of the 
published HUS incidence rates in different countries 
[?I-351. Even after exclusion of Argentina, which has 
a much higher incidence than any other country [35], 
the range is large: 1.08-5.8 cases/100000 in children 
less than 5 years old and 0.2-2.0 in children less than 
15 years old. N o  data are available on the incidence in 
adults [7]. Variations in data-collection methods may 
account for part of this variation and could, for 
instance, explain the important discrepancy between 
the data from four French departnients in 1982-93 [23] 
and those from the whole of France in 1993-95 “21. 
Table 2 Serotypes and virulence factors of the 13 VTEC isolates from HUS cases 
VT2 + eaeA Entero- No Virulence 
Srrotype Number VT2 VT2vh-a gene hemolysin &Hemolysin hemolysin plasmid 
0157:H7 a 9 
026:Hl l  1 
0 12 1 :H - 1 
0145:H- 1 
O172:H - 1 
Total 13 
6 3 9 9 0 0 9 
1 
1 0 1 1 0 ( 1  1 
1 0 
1 
I 1 
1 0 1 
1 0 1 0 
10 3 13 11 1 1 13 
0 0 1 1 0 
n 1 
0 
’Belonging to the following phage typcs (PT): PT 2 (two btrains), PT 4 (three strains), PT 49 (three strains) 
or RIINC (reaction does not conform to the phage types defined until now; one strain). 
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Table 3 Comparison of the annual incidence of HUS in different countries 
Incidence per Incidence per 
Country <5 years old <15 years old studied Reference 
100 000 children 100 000 children Year(s) 
Europe 
Austria 
Belgium 
France 
France (four departments) 
Germany (northern part) 
Italy 
The Netherlands 
UK 
North America 
Canada 
Canada (Alberta) 
USA (King County, Washington) 
USA (King County, Washington) 
USA (King County, Washington) 
USA (Maryland and Washington DC) 
USA (Minnesota) 
USA (Minnesota) 
USA (Oregon) 
USA (Utah) 
N R  
4.3 
1.78 
4.61 
2.7 
N R  
2.0 
N R  
3.1 1 
4.5 
N R  
N R  
N R  
1.6 
5.8 
2.65 
N R  
1 .m 
0.37 
1.8 
0.72 
N R  
1 .o 
N R  
0.2 
0.79 
1.44" 
N R  
0.69 
1.77 
1.74 
0.26h 
0.5" 
2 . v  
0.97' 
1.42 
South America 
Argentina (Buenos Aires and suburbs) 11.7 N R  
1995 
1996 
1993-95 
1983-93 
1986-91 
1988-92 
? 
1985-88 
1986-88 
1987-91 
1971-75 
1976-80 
1981-86 
1979-83 
1979 
1988 
1979-82 
1971-90 
1989 1351 
.'From 0.97 (Ontario) to 2.78 (Alberta): hchildren <21 years old: 'children <18 years old. 
N R ,  not reported 
The incidence rates that we determined in this Belgian 
study are closer to the North American rates, which 
tend to be higher than those observed in European 
countries. This could be due in part to a more 
complete recording of cases thanks to the active follow- 
up in the present study: several reminders were sent to 
all participants and, in addition, centers reporting no or 
only a few cases were telephoned. However, the present 
incidence could be still higher in North America and 
the UK, since most data from these countries date from 
the 1970s and the 1980s, while the numbers ofreported 
sporadic VTEC infection cases and of outbreaks are 
increasing [7,29,36,37]. 
Evidence of VTEC infection could be demon- 
strated in 23 of 36 patients from whom either stools or 
serum or both were available. When only children or 
patients with diarrhea were considered, the proportions 
increased to 22 of 30 and 21 of 29 respectively. These 
figures are rather low, as compared, for instance, with 
French data, where 86% of children with HUS had a 
laboratory diagnosis ofVTEC infection [22]. This does 
not mean, however, that none of the other patients had 
VTEC infection; it is known that, at the time of 
admission with HUS diagnosis, VTEC is no longer 
detectable in many patients [38], especially if antibiotics 
have already been given before stool collection, as in 
more than half of our patients for whom this 
information was available (data not shown). Moreover, 
the serologic investigations are limited in two ways: we 
investigated a restricted number of serotypes, and in 
many patients no late serum sample was available. 
As already reported by other authors, it is 
worthwhile looking for VTEC infection even in cases 
where VTEC is not expected, as in patients without 
diarrhea [25] and in adults [39,40]. For instance, in our 
study, two children without diarrhea and a 69-year-old 
woman had VTEC infection. In addition, all urinary 
tract E. coli isolates from HUS patients should be tested 
for toxin production since HUS has recently been 
associated with cases of urinary tract infection [41,42]. 
In a screening for VTEC in unselected stool 
samples submitted for culture in the Academisch 
Ziekenhuis Vrije Universiteit Brussel, only one-fifth of 
all VTEC isolates belonged to serotype 0157:H7 or its 
non-motile variant 0157:H- [9]. However, in this 
HUS study, when the patient with a positive PCR but 
with no VTEC isolate was excluded, and the patient 
with double positive serologic tests was counted twice, 
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0157  infection was diagnosed in 17 of the 22 patients 
with laboratory-confirmed VTEC infection and non- 
0157  infection in only six. This predominance of 
serogroup 0 1 5 7  has also been observed in other Euro- 
pean countries [8,22,24,43,44]. In France, although 
previous studies demonstrated a leading role for non- 
0157  VTEC in HUS [45,46], recent data showed 0157  
VTEC to be associated with 91% of HUS cases [22]. 
All 13 VTEC strains isolated here (including the 
four non-0157 isolates) produced the VT2-type toxin, 
combined with the VT2vh-a variant toxin in three 
0157:H7 strains, possessed the eae,4 gene and the 
large-sized virulence plasmid, and produced entero- 
hemolysin (except for two strains that were a- or non- 
hemolytic). VT2-producing non-0157 strains that also 
possess other virulence factors were only exceptionally 
isolated from unselected stool specimens: only three of 
55 VT3 or VTl+VT2-positive strains were m,4  
positive [9]. By contrast, most eueL4-positive strains 
produced VT1 and were more frequent in patients 
with diarrhea than in patients without diarrhea. The 
simultaneous presence of VT3 and the eae,l gene might 
explain the high pathogenicity of most 0 1  57 strains 
[47] and of many non-0157 VTEC strains isolated in 
HUS cases [46]. O f  the four non-0157 serotypes, one 
of them, 036:H11, has already repeatedly been isolated 
from HUS [3] and is considered to be enterohemor- 
rhagic. However, while VT7-producing 076:H 1 1 
strains have rarely been described, several HUS isolates 
presented this characteristic [46,48]. The three other 
serogroups were already identified in HUS cases, 
although rarely [3,12]. 0 1 7 3  is a recently established 
serogroup 1.191 but we isolated it in 1988 in a baby 
with HUS and reported this under its temporary 
denomination, 0“C70:86” [ 121. 
In conclusion, the HUS incidence rate found in 
this study and the high morbidity and mortality linked 
to this syndrome warrant further registration of 
pediatric and post-diarrheic adult HUS cases and also 
examination of stools for both 0 1 5 7  and non-0157 
VTEC strains. Methods are available that detect not 
only non-0157 VTEC strains but also atypical 
sorbitol-positive 0 157 strains as described in Germany 
[74] and other organisms producing VTs that have 
sometimes been involved in HUS, such as Citvobacter 
jieundii [50] and Eiiterobactcr cloacae [5 11. Further study 
of the E. coli serotypes and accessory virulence factors 
associated with HUS is needed to define better which 
VTEC isolates can cause this syndrome. This will 
contribute to a better understanding of the sources of 
infection, which seem to be different in continental 
Europe and in North America and the UK IS]. 
Implementation of efficacious quality control programs 
by food microbiologists will only be possible if these 
data are available. 
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